The only known cure for primary hyperparathyroidism is surgical removal of one or more
parathyroid glands. Some patients however, do not fulfill criteria for surgery or do not want
to undergo a procedure due to fear of the associated risks. Therefore a medical alternative
This study aims to evaluate the effects of Denosumab alone, and in combination with
Cinacalcet, as a medical treatment for patients suffering from primary hyperparathyroidism,
with mild osteoporosis. To the best of our knowledge no previously reported randomized
controlled trial has investigated the use of denosumab in primary hyperparathyroidism.
60 patients will be enrolled in three different treatment-groups: 20 receiving both Denosumab
and Cinacalcet, 20 Denosumab and placebo and 20 placebo and placebo. Patients included do not
meet the criteria for, or have no wish for a surgical procedure.
By combining the two drugs, this study could possibly contribute to the discovery of a
realistic medical alternative to surgery. It is expected that the therapy will be able to
both control s-calcium and s-intact parathyroid hormone (iPTH), and simultaneously enhance
bone-structure. The therapy thus has the potential of preventing fractures and possibly other
long-term effects of primary hyperparathyroidism such as formation of kidney stones, and
coronary calcification. Another objective of this project is to investigate whether the
combined therapy can facilitate an actual reset of the Calcium-sensing receptor, and thereby
de facto cure the disease.